Status:
COMPLETED
Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL
Lead Sponsor:
SymBio Pharmaceuticals
Conditions:
Diffuse Large B Cell Lymphoma
Eligibility:
All Genders
20+ years
Brief Summary
This study is a follow-up study to update the survival time data (overall survival, progression-free survival, and duration of response) of the subjects who received SyB L-0501 at least once in Phase ...
Eligibility Criteria
Inclusion
- Subjects who received the investigational product at least once in Study 2017002
- Subjects who or whose legal representatives gave written informed consent to provision of data pertaining to this study
Exclusion
- 1\. Subjects whose death was confirmed during the outcome investigation period in Study 2017002
Key Trial Info
Start Date :
March 26 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 11 2020
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04354402
Start Date
March 26 2020
End Date
November 11 2020
Last Update
April 18 2023
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Nagoya, Aichi-ken, Japan
2
Research Site
Matsuyama, Ehime, Japan
3
Research Site
Ōta, Gunma, Japan
4
Research Site
Fukuyama, Hiroshima, Japan